MDGL logo

Madrigal Pharmaceuticals, Inc. (MDGL) Cash From Financing

Annual CFF:

$735.06M+$139.95M(+23.52%)
December 31, 2024

Summary

  • As of today, MDGL annual cash from financing is $735.06 million, with the most recent change of +$139.95 million (+23.52%) on December 31, 2024.
  • During the last 3 years, MDGL annual cash from financing has risen by +$563.83 million (+329.27%).
  • MDGL annual cash from financing is now at all-time high.

Performance

MDGL Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherMDGLcash flow metrics

Quarterly CFF:

$1.74M-$6.90M(-79.85%)
June 30, 2025

Summary

  • As of today, MDGL quarterly cash from financing is $1.74 million, with the most recent change of -$6.90 million (-79.85%) on June 30, 2025.
  • Over the past year, MDGL quarterly cash from financing has dropped by -$132.38 million (-98.70%).
  • MDGL quarterly cash from financing is now -99.70% below its all-time high of $573.71 million, reached on March 31, 2024.

Performance

MDGL Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherMDGLcash flow metrics

TTM CFF:

$37.61M-$132.38M(-77.87%)
June 30, 2025

Summary

  • As of today, MDGL TTM cash from financing is $37.61 million, with the most recent change of -$132.38 million (-77.87%) on June 30, 2025.
  • Over the past year, MDGL TTM cash from financing has dropped by -$1.17 billion (-96.88%).
  • MDGL TTM cash from financing is now -96.88% below its all-time high of $1.21 billion, reached on June 30, 2024.

Performance

MDGL TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherMDGLcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

MDGL Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+23.5%-98.7%-96.9%
3Y3 Years+329.3%-96.5%-58.1%
5Y5 Years+10000.0%+1497.3%+8094.8%

MDGL Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+329.3%-99.7%>+9999.0%-96.9%at low
5Y5-Yearat high>+9999.0%-99.7%>+9999.0%-96.9%+8094.8%
All-TimeAll-Timeat high>+9999.0%-99.7%+104.9%-96.9%+239.3%

MDGL Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2025
-
$1.74M(-79.8%)
$37.61M(-77.9%)
Mar 2025
-
$8.64M(-56.3%)
$170.00M(-76.9%)
Dec 2024
$735.06M(+23.5%)
$19.77M(+165.0%)
$735.06M(-38.5%)
Sep 2024
-
$7.46M(-94.4%)
$1.20B(-1.0%)
Jun 2024
-
$134.12M(-76.6%)
$1.21B(+8.2%)
Mar 2024
-
$573.71M(+19.5%)
$1.12B(+87.5%)
Dec 2023
$595.12M(+89.9%)
$479.92M(+2351.1%)
$595.12M(+56.8%)
Sep 2023
-
$19.58M(-54.4%)
$379.54M(+5.4%)
Jun 2023
-
$42.93M(-18.5%)
$359.96M(-1.7%)
Mar 2023
-
$52.69M(-80.1%)
$366.14M(+16.8%)
Dec 2022
$313.45M(+83.1%)
$264.34M(>+9900.0%)
$313.45M(+356.8%)
Sep 2022
-
$0.00(-100.0%)
$68.62M(-23.5%)
Jun 2022
-
$49.11M(>+9900.0%)
$89.72M(-13.9%)
Mar 2022
-
$0.00(-100.0%)
$104.14M(-39.2%)
Dec 2021
$171.24M(+3265.5%)
$19.50M(-7.6%)
$171.24M(+9.5%)
Sep 2021
-
$21.10M(-66.8%)
$156.36M(+15.3%)
Jun 2021
-
$63.54M(-5.3%)
$135.61M(+87.9%)
Mar 2021
-
$67.09M(+1349.4%)
$72.18M(+1318.7%)
Dec 2020
$5.09M(+2065.1%)
$4.63M(+1222.6%)
$5.09M(+1008.5%)
Sep 2020
-
$350.00K(+221.1%)
$459.00K(+218.8%)
Jun 2020
-
$109.00K(>+9900.0%)
$144.00K(-5.3%)
Mar 2020
-
$0.00(0.0%)
$152.00K(-35.3%)
Dec 2019
$235.00K(-99.9%)
$0.00(-100.0%)
$235.00K(-72.2%)
Sep 2019
-
$35.00K(-70.1%)
$845.00K(-33.0%)
Jun 2019
-
$117.00K(+41.0%)
$1.26M(-99.6%)
Mar 2019
-
$83.00K(-86.4%)
$314.15M(-0.1%)
Dec 2018
$314.33M(+80.9%)
$610.00K(+35.3%)
$314.33M(-30.0%)
Sep 2018
-
$451.00K(-99.9%)
$449.25M(+0.1%)
Jun 2018
-
$313.01M(>+9900.0%)
$448.80M(+163.0%)
Mar 2018
-
$265.00K(-99.8%)
$170.67M(-1.8%)
Dec 2017
$173.81M(+1102.5%)
$135.53M(>+9900.0%)
$173.81M(+292.9%)
Sep 2017
-
$0.00(-100.0%)
$44.23M(-3.5%)
Jun 2017
-
$34.88M(+926.2%)
$45.86M(+168.1%)
Mar 2017
-
$3.40M(-42.9%)
$17.10M(+18.3%)
Dec 2016
$14.45M(+338.0%)
$5.95M(+266.3%)
$14.45M(+46.7%)
Sep 2016
-
$1.63M(-73.5%)
$9.85M(+136.5%)
Jun 2016
-
$6.13M(+716.7%)
-$27.01M(-524.6%)
Mar 2016
-
$750.00K(-44.4%)
$6.36M(+92.8%)
Dec 2015
$3.30M
$1.35M(+103.8%)
$3.30M(+1019.2%)
DateAnnualQuarterlyTTM
Sep 2015
-
-$35.24M(-189.2%)
-$359.00K(-100.6%)
Jun 2015
-
$39.50M(+1809.1%)
$60.69M(-19.5%)
Mar 2015
-
-$2.31M(-0.1%)
$75.37M(-11.6%)
Dec 2014
$85.30M(+23.5%)
-$2.31M(-108.9%)
$85.30M(-2.6%)
Sep 2014
-
$25.82M(-52.3%)
$87.61M(+41.8%)
Jun 2014
-
$54.17M(+611.2%)
$61.79M(+698.6%)
Mar 2014
-
$7.62M(+6247.5%)
$7.74M(-91.8%)
Dec 2013
$69.04M(-40.2%)
-
-
Jun 2013
-
$120.00K(-99.0%)
$94.42M(-0.3%)
Mar 2013
-
$12.28M(-78.9%)
$94.75M(-18.0%)
Dec 2012
$115.52M(+214.4%)
$58.07M(+142.5%)
$115.52M(+101.3%)
Sep 2012
-
$23.95M(+5331.1%)
$57.37M(+72.4%)
Jun 2012
-
$441.00K(-98.7%)
$33.29M(-50.8%)
Mar 2012
-
$33.05M(>+9900.0%)
$67.68M(+84.2%)
Dec 2011
$36.74M(-18.6%)
-$69.00K(+48.9%)
$36.74M(-12.3%)
Sep 2011
-
-$135.00K(-100.4%)
$41.90M(-25.2%)
Jun 2011
-
$34.84M(+1556.5%)
$55.99M(+167.8%)
Mar 2011
-
$2.10M(-58.7%)
$20.91M(-53.7%)
Dec 2010
$45.16M(+2221.0%)
$5.10M(-63.5%)
$45.16M(+13.8%)
Sep 2010
-
$13.96M(+5750.2%)
$39.68M(+57.3%)
Jun 2010
-
-$247.00K(-100.9%)
$25.22M(+1.4%)
Mar 2010
-
$26.35M(+6980.2%)
$24.87M(+1268.2%)
Dec 2009
-$2.13M(-11.7%)
-$383.00K(+24.2%)
-$2.13M(+11.3%)
Sep 2009
-
-$505.00K(+14.6%)
-$2.40M(+7.7%)
Jun 2009
-
-$591.00K(+9.1%)
-$2.60M(-13.0%)
Mar 2009
-
-$650.00K(+0.5%)
-$2.30M(-20.7%)
Dec 2008
-$1.91M(-104.3%)
-$653.00K(+7.2%)
-$1.91M(-25.2%)
Sep 2008
-
-$704.00K(-140.3%)
-$1.52M(-62.1%)
Jun 2008
-
-$293.00K(-14.5%)
-$939.00K(+14.5%)
Mar 2008
-
-$256.00K(+4.8%)
-$1.10M(-102.5%)
Dec 2007
$43.88M(+11.7%)
-$269.00K(-122.3%)
$43.88M(-0.2%)
Sep 2007
-
-$121.00K(+73.2%)
$43.96M(-0.3%)
Jun 2007
-
-$452.00K(-101.0%)
$44.08M(-1.0%)
Mar 2007
-
$44.73M(>+9900.0%)
$44.53M(>+9900.0%)
Dec 2006
$39.29M(+939.7%)
-$192.00K(+71.8%)
-$192.00K(+71.8%)
Dec 2005
$3.78M(-95.5%)
-
-
Mar 2005
-
-$681.00K
-$681.00K
Dec 2004
$84.28M(+18.5%)
-
-
Dec 2003
$71.12M
-
-

FAQ

  • What is Madrigal Pharmaceuticals, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Madrigal Pharmaceuticals, Inc.?
  • What is Madrigal Pharmaceuticals, Inc. annual cash from financing year-on-year change?
  • What is Madrigal Pharmaceuticals, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Madrigal Pharmaceuticals, Inc.?
  • What is Madrigal Pharmaceuticals, Inc. quarterly cash from financing year-on-year change?
  • What is Madrigal Pharmaceuticals, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Madrigal Pharmaceuticals, Inc.?
  • What is Madrigal Pharmaceuticals, Inc. TTM cash from financing year-on-year change?

What is Madrigal Pharmaceuticals, Inc. annual cash from financing?

The current annual cash from financing of MDGL is $735.06M

What is the all-time high annual cash from financing for Madrigal Pharmaceuticals, Inc.?

Madrigal Pharmaceuticals, Inc. all-time high annual cash from financing is $735.06M

What is Madrigal Pharmaceuticals, Inc. annual cash from financing year-on-year change?

Over the past year, MDGL annual cash from financing has changed by +$139.95M (+23.52%)

What is Madrigal Pharmaceuticals, Inc. quarterly cash from financing?

The current quarterly cash from financing of MDGL is $1.74M

What is the all-time high quarterly cash from financing for Madrigal Pharmaceuticals, Inc.?

Madrigal Pharmaceuticals, Inc. all-time high quarterly cash from financing is $573.71M

What is Madrigal Pharmaceuticals, Inc. quarterly cash from financing year-on-year change?

Over the past year, MDGL quarterly cash from financing has changed by -$132.38M (-98.70%)

What is Madrigal Pharmaceuticals, Inc. TTM cash from financing?

The current TTM cash from financing of MDGL is $37.61M

What is the all-time high TTM cash from financing for Madrigal Pharmaceuticals, Inc.?

Madrigal Pharmaceuticals, Inc. all-time high TTM cash from financing is $1.21B

What is Madrigal Pharmaceuticals, Inc. TTM cash from financing year-on-year change?

Over the past year, MDGL TTM cash from financing has changed by -$1.17B (-96.88%)
On this page